Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21667288 | 0.83 | SLC6A2 (0.36) | CA2SLC6A2MMP12MMP13 | |
| SCHEMBL19599275 | 0.82 | ALDH1A1 (0.52) | CA2SLC6A2MMP12MMP13 | |
| SCHEMBL658697 | 0.82 | LMNA (0.43) | CA2SLC6A2MMP12MMP13 | |
| SCHEMBL8260632 | 0.82 | CA2 (0.63) | CA2 | |
| SCHEMBL18923481 | 0.82 | CA2 (0.40) | CA2SLC6A2MMP12MMP13 | |
| SCHEMBL19604291 | 0.79 | GRIA4 (0.41) | CA2SLC6A2MMP12MMP13 | |
| SCHEMBL2600037 | 0.79 | ESR1 (0.50) | ENPP2KCNJ1KCNH2EPHX2NR1H4 | |
| SCHEMBL8306535 | 0.79 | EPHX2 (0.43) | TMEM97ENPP2KCNJ1KCNH2EPHX2 | |
| SCHEMBL8566646 | 0.79 | EPHX2 (0.43) | TMEM97ENPP2KCNJ1KCNH2EPHX2 | |
| SCHEMBL6793165 | 0.77 | CA2 (0.67) | ENPP2KCNJ1KCNH2CA2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10458995-B2 | Combinatorial synthesis and biomarker development | TEN30 BIOSCIENCES, INC. | 2019-10-29 | — | — | US | disclosed |
| US-20190113521-A1 | COMBINATORIAL SYNTHESIS AND BIOMARKER DEVELOPMENT | TEN30 BIOSCIENCES, INC. | 2019-04-18 | — | — | US | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20150316849-A1 | RESIST UNDERLAYER FILM FORMING COMPOSITION CONTAINING SILICON HAVING ESTER GROUP | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120270741-A1 | BIOMARKER DISCOVERY IN COMPLEX BIOLOGICAL FLUID USING BEAD OR PARTICLE BASED LIBRARIES AND DIAGNOSTIC KITS AND THERAPEUTICS | OPKO PHARMACEUTICALS, LLC | 2012-10-25 | — | — | US | disclosed |
| US-20120270741-A1 | BIOMARKER DISCOVERY IN COMPLEX BIOLOGICAL FLUID USING BEAD OR PARTICLE BASED LIBRARIES AND DIAGNOSTIC KITS AND THERAPEUTICS | OPKO PHARMACEUTICALS, LLC | 2012-10-25 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | TMEM97 4031/4885ENPP2 1958/4885KCNJ1 4321/4885 |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | TMEM97 4031/4885ENPP2 1958/4885KCNJ1 4321/4885 |
| US-20120270741-A1 | BIOMARKER DISCOVERY IN COMPLEX BIOLOGICAL FLUID USING BEAD OR PARTICLE BASED LIBRARIES AND DIAGNOSTIC KITS AND THERAPEUTICS | PMP22, TNFSF11, SELPLG | TMEM97 1200/4885ENPP2 416/4885KCNJ1 4604/4885 |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | VIP, PROKR1, PGC | TMEM97 3923/4885ENPP2 504/4885KCNJ1 3635/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | TMEM97 4031/4885ENPP2 1958/4885KCNJ1 4321/4885 |
| US-20190113521-A1 | COMBINATORIAL SYNTHESIS AND BIOMARKER DEVELOPMENT | APP, PSEN2, PSEN1 | TMEM97 4766/4885ENPP2 2286/4885KCNJ1 4880/4885 |
| US-10458995-B2 | Combinatorial synthesis and biomarker development | APP, PSEN2, PSEN1 | TMEM97 4765/4885ENPP2 2245/4885KCNJ1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.